Chk1, coupled with DNA damage and induction of apoptosis. Here we have examined, which of these phenomena are necessary for CDK inhibitors to have an anti-proliferative effect. We find that 24 hours treatment with either a primarily CDK2-specific, or a primarily CDK7/9-specific, antagonist eliminates proliferative potential even if apoptosis is blocked and the tendency of CDK inhibition to result in DNA damage is overcome by expression of recombinant Chk1. Loss of proliferative potential is correlated with irreversible suppression of biomarkers of cell cycle progression. CDK inhibitors dramatically reduced levels of the anti-apoptotic proteins, Mcl-1 and XIAP, but siRNA-mediated suppression of Mcl-1 and XIAP did not induce cell death in the osteosarcoma cells used in this study. Finally, we found that many literature CDK inhibitors do not effectively suppress the CDK/cyclin complexes responsible for cell cycle progression at the minimum doses required to block proliferation: some are only effective after a substantial delay and may act via inhibition of CDK7.
Introduction
Cyclin-dependent kinases (CDKs) play cardinal roles in proliferation. CDK activation is required for commitment to another round of division, for the transition from G 1 to S phase and for entry into mitosis. 1 These three functions were once attributed to CDK4 or 6, CDK2 or 3, and CDK1, respectively, but recent results indicate that CDK1 can perform all the essential functions of the five cell cycle CDKs. 2 The identity of the regulatory cyclin subunit, and the details of how it controls the subcellular localization and activation dynamics of its CDK partners, may be more important for defining the function of CDK/cyclin complexes. 3 All the above CDK/ cyclin complexes require an activating phosphorylation to become active, which is performed by another CDK, CDK7/cyclin H. 4 As a member of the TFIIH complex, CDK7 also plays a role in RNA polymerase II transcription regulating initiation by phosphorylating the carboxy-terminal repeat domain (CTD) of RNA polymerase. A number of other CDKs also play roles in transcription, including the P-TEFb component, CDK9. 5 CDK activity is often deregulated in transformed cells, e.g., by loss of stoichiometric inhibitor proteins such as p16 and p27. 6 This cancer-specific deregulation led to the CDKs being a major target of the efforts to identify therapeutically useful protein kinase inhibitors stimulated by the success of imatinib mesylate (Gleevec) in treating chronic myelogenous leukemia. 7 Numerous small molecule inhibitors of CDKs have now been identified that block cell cycle progression and induce apoptosis in cancer cells. 8 The selectivity of known inhibitors is variable, but few are specific for either cell cycle or transcriptional CDKs. However, as some CDK inhibitors are effective at treating xenografted human tumors implanted into immunocompromised mice, 9 biased killing of cancer cells appears possible with certain selectivity profiles. The mechanism by which CDK inhibitors kill cancer cells has been controversial. An early proposal was that CDK2 activity is required to suppress E2F-1 driven pro-apoptotic transcription triggered by oncogenic signaling, 10 but the dispensability of CDK2 for the growth of many cancer cell lines 11 has led to other rationales being considered. Recently, attention has been focused on the ability of CDK inhibitors to suppress expression of the short half-life anti-apoptotic proteins XIAP (a caspase inhibitor) and Mcl-1 (a Bcl-2 family member) via inhibition of CDK7 and/or CDK9. As proposed by Koumenis and Giacca in 1997, 12 transformed cells may be particularly sensitive to interruptions in the synthesis of rapidly turned-over anti-apoptotic proteins. CDK7 and CDK9 are frequently targeted by nominal cell cycle CDK inhibitors 13 and the cytotoxicity of the best-characterized examples, roscovitine and flavopiridol, has been attributed to consequent Mcl-1 and XIAP depletion. [14] [15] [16] Loss of CDK2 activity, however, also evokes a pathological checkpoint response associated with DNA damage, impaired DNA repair and loss of expression of the Chk1 kinase, which likely also contributes to the toxicity of CDK inhibitors. [17] [18] [19] Cells with defective BRCA1 function may be particularly susceptible to death via this mechanism. 19 The lack of clarity around the mode-of-action of CDK inhibitors makes it unclear which CDK/cyclin complexes should be inhibited to maximize chances of success in cancer therapy. To aid our efforts in this area, we set out to establish how small molecule CDK inhibitors kill U2-OS osteosarcoma cells, a cell line frequently used to study the roles of CDK/cyclin complexes. [18] [19] [20] [21] [22] We were particularly interested in the consequences of blockading CDK2 and CDK1, the CDKs responsible for triggering S-phase and driving mitosis. When literature inhibitors were examined to select reagents suitable for use in this study, none of the commercially available compounds tested possessed both of the properties we considered essential: good potency on cells and confidence that the anti-proliferative effects of the compounds are mediated by inhibition of cell cycle CDK/ cyclin complexes. Consequently, we used VER-54505, a pyrazolopyrimidine synthesized as part of a medicinal chemistry effort to find CDK inhibitors suitable for cancer therapy. 23 VER-54505 induced caspase-dependent apoptosis and a DNA damage response linked to Chk1 depletion, but interestingly, neither of these effects was required for transient treatment with VER-54505 to permanently block proliferation.
Results
Biomarkers of cell cycle progression do not recover after 24 hours exposure to apoptosis-evoking doses of the CDK2 inhibitor, VER-54505. Given their essential role in cell division, continuous exposure to CDK inhibitors will suppress the growth of both transformed and normal cells. Consequently, some form of transient treatment will be necessary if CDK inhibitors are to be used for anti-cancer therapy. It is therefore important to know how long a blockade has to be imposed for tumor cell viability to be lost. VER-54505, a novel CDK2 inhibitor primarily active vs. CDK2, was selected for this study because of its ability to rapidly suppress biomarkers of cell cycle related CDK/cyclin complex activity at low multiples of its GI 50 , the dose required to reduce final biomass by 50% in a growth/proliferation assay (Figs. S1 and S2). VER-54505 blocks entry into mitosis at lower doses than it suppresses DNA replication and is capable of forcing exit from mitosis (Fig. S3) . U2-OS cells plated at low density, were treated for 2 to 24 hours with VER-54505, then cultured without drug for 7 days to allow colony formation. High doses of the compound were tolerated if applied for ≤7 hours, but 24 hours treatment with 2x GI 50 VER-54505 reduced colony formation by <95% (Fig. 1A) . Though little apoptosis was evoked by 24 hours treatment with this dose, a large increase in the fraction of cells with sub-G 1 DNA content was seen after 48 and 72 hours treatment (Fig. 1B) . Significant PARP cleavage was observed in populations containing 20% or more sub-G 1 cells (data not shown, but also see Fig. 1C ). Removal of drug after 24 hours did not rescue U2-OS cells from subsequent apoptosis.
Given that 7 hours treatment with high doses of VER-54505 was well tolerated, we suspected that CDK inhibitors might impose substantial changes in cellular signaling without ill effect as long as the changes were reversed upon drug removal. Loss of viability should therefore be correlated with the subset of pharmacodynamic marker changes imposed by VER-54505, which were not reversed when the CDK inhibitor was washed out. Cells were thus treated for 24 hours with 0.5x to 4x GI 50 of VER-54505 and then lysed either immediately, or after 6 or 24 hours recovery without drug.
Low doses (0.5-1x GI 50 ) of VER-54505 suppressed phosphorylation of the retinoblastoma protein (Rb) on Ser249/Thr252 and histone H3 on Ser10, and also reduced expression of Chk1 (Fig. 1C) . The loss of Rb and histone H3 phosphorylation suggests suppression of CDK2 and CDK1 activity in cells; Rb Ser249/ Thr252 is a direct substrate for CDK2, [24] [25] [26] and histone H3 Ser10 is phosphorylated by Aurora B only during mitosis, 27 for which CDK1 activity is essential. Inhibition of Rb and Histone H3 phosphorylation was (at least in part) reversible, but the reduction imposed on Chk1 levels was longer-lasting. The higher doses (2-4x GI 50 ) of VER-54505 that were associated with loss of clonogenicity appeared to affect additional CDK complexes. VER-54505 at ≥2x GI 50 reduced phosphorylation of RNA polymerase II on Ser2 of the C-terminal heptapeptide repeat domain (an epitope phosphorylated by CDK9), 28 and suppressed XIAP and Mcl-1 expression. These doses also evoked phosphorylation of Histone H2AX on Ser139 (a marker of DNA damage) 29 and stimulated p53 expression. Though apoptotic markers were not apparent after 24 hours treatment with VER-54505, cleavage of caspase 7 and PARP was observed 6 and 24 hours after removal of ≥2x GI 50 VER-54505 (Fig. 1C) . The minimum dose of VER-54505 required to eliminate long term proliferative potential thus corresponds to the minimum dose required to induce apoptosis. It was striking, however, that after 24 hours treatment with ≥2x GI 50 VER-54505, Rb Ser249/Thr252 and histone H3 phosphorylation did not recover at all when drug is removed. The irreversible suppression of cyclin B1, cyclin E1 and Cdc25A observed at these doses may account for the lack of recovery of Rb and Histone H3 phosphorylation.
Is induction of apoptosis essential for the ability of transient treatment with CDK inhibitors to block further proliferation of U2-OS cells? The results above suggest that CDK inhibitors in part ablate long term proliferative potential by forcing cells into permanent cell cycle arrest. VER-54505, however, also induced programmed cell death, and we were keen to establish how important a role apoptosis played in the loss of clonogenicity. U2-OS cells were exposed to a range of doses of VER-54505 in the presence of absence of 20 μM zVAD-fmk, a cell-permeable irreversible inhibitor of multiple caspases. 30 VER-54505 was withdrawn after 24 hours, but exposure to the caspase inhibitors, if present, was maintained. zVAD-fmk substantially blocks the cleavage of caspase 3 and 7 to the active forms that is otherwise induced by VER-54505 ( Fig.  2A) and also prevents the appearance of cells with a sub-G 1 DNA content (Fig. 2B) . Consistent with the results shown in Figure 1B , 24 hours treatment with VER-54505 does not immediately reduce cell biomass below that observed prior to treatment (Fig. 2C ), but significant reductions are seen after a further 24 or 48 hours incubation (here without drug). Addition of zVAD-fmk substantially rescues cells from this CDK-inhibitor induced lethality confirming
Mode of action of the CDK inhibitor VER-54505
www.landesbioscience.com Cell Cyclecapacity of VER-54505 to deplete Mcl-1 and/or XIAP therefore does not account for its ability to induce apoptosis in U2-OS cells.
The loss of clonogenicity induced by treatment with the CDK7 inhibitor, BMS-387032, also correlates with its ability to impose a permanent cell cycle arrest. One of the CDK inhibitors that has entered clinical trials is BMS-387032, 9 also now known as SNS-032. BMS-387032 blocks DNA replication and entry into mitosis with approximately equal effectiveness, but fails to force exit from mitosis ( Fig. S3 ). During our efforts to identify a CDK2 inhibitor suitable for this work, we found that BMS-387032 is approximately equally effective at inhibiting CDK2, 7 and 9 in in vitro kinase assays (Fig.  S1 ). The surprisingly high potency of BMS-387032 vs. CDK7 and CDK9 has also been noted by Choong et al. 31 BMS-387032 is a highly effective suppressor of biomarkers of cell cycle related CDK activity in 24 hour treatments, but is relatively ineffective in shorter exposures, despite its greater ability to traverse cell membranes compared to VER-54505 (Fig. S2 ). Time course experiments revealed that phosphorylation of Ser5 residues within the RNA polymerase II C-terminal domain repeats was reduced within 30 minutes of addition of 2x GI 50 BMS-387032, but 4 to 7 hours were required for suppression of Ser2 phosphorylation (Fig. 5A ). Rb Ser249/Thr252 and Histone H3 Ser10 phosphorylation was only lost 7 to 16 hours after addition of drug, similar to the kinetics for loss of phosphorylation of CDK2 on Thr160, the critical activation loop threonine residue (Fig. 5A ). While CDK9 is suspected to phosphorylate RNA polymerase II on Ser2, 28 CDK7 is thought to be the critical kinase responsible for phosphorylation of both RNA polymerase II on Ser5 and CDK2 on Thr160. 32, 33 These data suggest that at the minimum effective dose, BMS-387032 may only suppress CDK7 activity. The delayed loss of biomarkers of CDK9 and CDK2 activity may be due to the time required for phosphorylation of the activating loop threonines of these kinases to be turned over.
An efficient inhibitor of CDK7 would be expected to evoke all the effects of a CDK2 inhibitor (albeit after a delay), but should also elicit additional responses via its effect on transcription. Short exposure to BMS-387032 is not, however, more lethal to U2-OS cells than corresponding treatments with a CDK2 inhibitor; as for VER-54505, 24 hours treatment was required to suppress proliferative potential ( Fig.  5B ) and, at 4x GI 50 , was sufficient to trigger apoptosis after a delay (Fig. 5C ). Nevertheless, we were keen to find out if BMS-387032, ablated proliferative potential by different means to a primarily CDK2-selective inhibitor, such as VER-54505.
U2-OS cells were treated for 24 hours with 0.5x to 4x GI 50 of BMS-387032 and then lysed either immediately, or after 6 or 24 hours recovery without drug. Similar to VER-54505, low doses (0.5-1x GI 50 ) of BMS-387032 suppressed Rb Ser249/Thr252 and histone H3 phosphorylation in a partially reversible manner, but BMS-387032 treatment had additional consequences not observed with low doses of VER-54505 (compare Figs. 5D with 1C) . Some of these effects were reversed upon drug removal, such as suppression that it occurs via caspase-dependent apoptosis. zVAD-fmk did not, however, rescue cells from either the block on proliferation or loss of clonogenicity imposed by VER-54505 ( Fig. 2C and D) . Apoptosis is therefore dispensable for the anti-proliferative effects of transient treatment with VER-54505.
Is suppression of Chk1 required for DNA damage, apoptosis or cell cycle arrest? VER-54505 reduces Chk1 levels (Fig. 1C) , confirming the results of Maude and Enders 18 obtained with the less selective CDK inhibitors, roscovitine and oloumucine. Chk1 has an important role in stabilizing stalled forks under conditions of replication stress, which CDK inhibition imposes due to reduced origin firing. 17, 18 This begs the question: how important is the ability of CDK inhibitors to suppress Chk1 for their potential to induce DNA damage, apoptosis, permanent cell cycle arrest and loss of clonogenicity? Transient transfection of pCMV-Chk1 increased Chk1 levels and prevented their suppression by VER-54505, but did not stop the CDK inhibitor evoking caspase activation (Fig.  3A) , or suppressing the colony forming potential of U2-OS cells (Fig. 3B ). Chk1 overexpression somewhat dampened the induction of H2AX phosphorylation by VER-54505, as did addition of the caspase inhibitor zVAD-fmk. Remarkably however, the combination of Chk1 overexpression and caspase inhibition completely prevented H2AX phosphorylation in response to VER-54505 addition (Fig.  3A) . Combined Chk1 overexpression and caspase inhibition did not allow Rb and Histone H3 phosphorylation to recover upon drug removal, and also failed to rescue long term proliferative potential (Fig. 3B) . The ability of VER-54505 to downregulate Chk1 therefore influences its ability to evoke DNA damage, but is dispensable for its ability to trigger apoptosis and impose a long-term cell cycle arrest.
VER-54505 induced apoptosis is not a consequence of depletion of Mcl-1 and XIAP. Several recent reports attribute the cytotoxicity of CDK inhibitors to suppression of Mcl-1 and XIAP expression; [14] [15] [16] this is proposed to unleash pro-apoptotic factors already present in transformed cells as a consequence of oncogenic signaling. There was a close correlation between the doses of VER-54505 required to suppress Mcl-1 and XIAP, with those that induced caspase and PARP cleavage. To establish if the apoptosis evoked by VER-54505 could be attributed to loss of Mcl-1 and/or XIAP, we suppressed their expression via RNA interference either singly, or together.
Immunoblots of U2-OS lysates prepared 48 to 72 hours post transfection indicated that siRNAs vs. Mcl-1 and XIAP dramatically reduced expression of the targeted gene; importantly, expression of both proteins could be stifled simultaneously (Fig. 4A) . Knocking down Mcl-1 or XIAP resulted in little increase in the fraction of cells with a sub-G 1 DNA content, although simultaneous depletion of both proteins increased the putative apoptotic fraction (at 72 hours post-transfection) from ~4% to ~8%. siRNA mediated depletion of Mcl-1, XIAP, or both proteins together, had little effect on the longterm proliferative potential of U2-OS cells and also failed to increase the toxicity of 24-hour treatments with VER-54505 (Fig. 4B) . The The similarity in biomarker responses evoked by clonogenicity-eliminating doses of BMS-387032 and VER-54505 suggested that the ability of BMS-387032 to induce apoptosis and DNA damage might also be dispensable for its effects on long term proliferative potential. As for VER-54505, addition of zVAD-fmk substantially rescues cells from BMS-387032 induced lethality, but not from a block on proliferation (data not shown), or clonogenicity (Fig. 5E) . Similarly, Chk1 overexpression (alone or in combination with zVAD addition) also failed to rescue the suppression of clonogenicity evoked by BMS-387032, even in a narrow quantitative sense (Fig. 5E ).
Discussion
CDK inhibitors have multiple effects on cancer cells: blocking cell cycle progression, inducing DNA damage and provoking apoptosis. We set out to establish which of these effects were required to eliminate the long term proliferative potential of U2-OS cells. Our particular interest was in the consequences of CDK2 inhibition, but we found many "CDK2" inhibitors described in the literature were heavily compromised by off-target effects. Of the compounds tested, VER-54505 proved the most effective modulator of CDK2 activity in cells and consequently was used in our studies. At doses that suppress phosphorylation of CDK2 substrates, 7 hour treatments with VER-54505 were tolerated, but 24 hour treatments eliminated the colony forming abilities of
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imposition of a sustained cell cycle arrest. Suppressing apoptosis with the cell-permeable caspase inhibitor, zVAD-fmk, had no effect on the ability of transient-treatment with VER-54505 to impair long-term proliferation of U2-OS cells, though cells were rescued from much of the cytotoxicity it normally caused. Therefore, at least in U2-OS cells, the apoptosis evoked by CDK inhibition merely accelerates the demise of cells whose ability to leave a colony of descendents has already been eliminated. The DNA damage provoked by CDK inhibitors is believed to result from the suppression of Chk1 expression, which while not toxic in itself, becomes so under conditions of replication stress. 18 U2-OS cells. VER-54505 initially increased the fraction of cells in G 2 , but later provoked apoptosis, even if drug had been removed at 24 h. Doses of VER-54505 that eliminated long term proliferative potential blocked CDK2 and CDK9 activity, stifled expression of the anti-apoptotic proteins Mcl-1 and XIAP, but also suppressed Chk1 expression and induced the H2AX Ser139 phosphorylation associated with DNA damage.
Substantial suppression of long term proliferation was also imposed by lower doses of VER-54505 that failed to evoke apoptosis or DNA damage, raising the possibility that transient treatment with CDK inhibitors might be able to eliminate clonogenicity simply by them locked in a low CDK/cyclin activity state reminiscent of G 0 .
The loss of Cdc25A may also interfere with activation of CDK4/ cyclin D complexes, 40 reducing their ability to restore Rb phosphorylation by more than would be expected by the modest effect 2x GI 50 VER-54505 has on cyclin D1 levels. Though apoptosis might not be required for the loss of clonogenicity, the induction of programmed cell death is obviously sufficient to prevent further proliferation. A somewhat surprising finding of this work is that, at least in U2-OS cells, CDK inhibition does not trigger apoptosis via Mcl-1 and XIAP depletion. When we curbed expression of these anti-apoptotic factors from U2-OS cells by RNA interference, we did not observe dramatic apoptosis or a reduction in clonogenicity. Though this result is discordant with certain recent reports, [14] [15] [16] it is not inconsistent with them as Mcl-1 and XIAP are merely the unstable members of two wider families of anti-apoptotic proteins. 41 Logically, one would expect CDK inhibitors to only kill cells via depletion of Mcl-1 or XIAP, if they made a major quantitative contribution to the complement of anti-apoptotic proteins in the cell line under test.
We have not established why transient treatment with CDK-inhibitors induces apoptosis in U2-OS cells, but it is interesting to note that VER-54505 only induces apoptosis at doses that reduce phosphorylation of RNA polymerase II on Ser2, likely indicating suppression of CDK9. 28 Strengthening this correlation, BMS-387032 evokes both downregulation of RNA polymerase II Ser2 phosphorylation and some degree of caspase activation at all doses tested. The apoptosis provoked by CDK inhibitors in U2-OS cells may therefore be due to inhibition of transcriptional CDKs rather than CDK2.
Despite the ability of BMS-387032 to evoke some apoptosis at low doses, it only ablated colony forming potential at doses where Rb and Histone H3 phosphorylation did not recover upon drug removal. As for VER-54505, overexpression of Chk1 and blockade of caspase activity made no difference to the dose of BMS-387032 required to reduce or eliminate colony formation. In addition, Mcl-1 and or XIAP depletion did not modulate the toxicity of BMS-387032 (unpublished results). This indicates that the greater Following H2AX Ser139 phosphorylation as a marker, we found that overexpression of Chk1 reduced the amount of DNA damage caused by VER-54505, but did not prevent the compound triggering caspase activation. We suspect that the residual DNA damage evoked by VER-54505 in Chk1-overexpressing cells may be a consequence of double-strand breaks caused by nucleosome cleavage in apoptosis, 34 as combining Chk1 overexpression with addition of a caspase inhibitor prevented VER-54505 provoking any H2AX phosphorylation. Combined blockade of the ability of VER-54505 to induce apoptosis and DNA damage did not, however, stop treatment with the compound eliminating the colony forming potential of U2-OS cells.
VER-54505 suppresses CDK2 activity within 10 minutes of addition (see Fig. S2B ). So why might inhibition of cell cycle CDK/ cyclin be tolerated for 7 hours, but evoke a long-term cell cycle arrest if the inhibition is sustained for 24 hours? As Chk1 overexpression prevents VER-54505 inducing DNA damage but fails to enable recovery of cell cycle progression, we do not think that the cell cycle arrest requires CDK inhibitor-mediated collapse of replication forks. We also suspect that the p53 response observed, which is probably evoked by inhibition of transcriptional CDK activity preventing Hdm2 synthesis, 35 is also dispensable for the arrest; significant clonogenicity is lost at doses of VER-54505 that fail to induce p53, and the levels of p53 and p21 have dropped back to normal 24 hours after removal of drug. Instead, we propose that the ability of CDK inhibitors to impose a sustained cell cycle arrest after 24 hours, but not 7 hours, treatment rests on their ability to interrupt the synthesis of cyclins and CDK-activating phosphatases. When VER-54505 is present, Rb is dephosphorylated and is free to bind to and inactivate E2F1, resulting reduced synthesis of proteins encoded by E2F1-responsive genes such as Chk1 Cdc25A, cyclin E1 and cyclin B1, [36] [37] [38] [39] which in time translates into a dramatic reduction in the levels of these proteins (as observed in Fig. 1C) . Once the levels of cyclin E1 and Cdc25A drop below a certain threshold (crossed sometime between 7 and 24 hours of drug exposure) cells lose the ability to re-phosphorylate and inactivate Rb and so are unable to restore E2F1-mediated transcription when drug is removed, leaving (06-570); and Santa Cruz (Heidelburg, Germany) for anti-Cdc25A (sc97), anti-Mcl-1 (sc20679), anti-p21 (sc397) and anti-RNA pol II CTD Ser5 (sc13583). HRP-conjugated secondary antibodies were from by GE Healthcare Lifesciences. Rb Ser249/Thr252 phosphorylation was also assayed using an ELISA kit from Biosource (Nivelles, Belgium) according to the manufacturers instructions. DNA replication was measured using the Cell Proliferation ELISA kit from Roche Applied Science. Flow cytometry. After drug treatment for the indicated times, the entire population of cells was fixed in ice-cold 30% PBS/70% EtOH on ice for 1-2 hours. Cells were resuspended in PBS + propidium iodide (50 μg/ml) and DNAse free-RNAse A (50 μg/ml) and incubated at 37°C for 60 minutes. The DNA content of each cell was measured using a Beckon Dickinson FACScan instrument. Sub G 1 , G 1 , S-phase and G 2 /M populations were identified by reference to untreated populations of the same cell line.
Clonogenic assays. Cells were detached by trypsin-EDTA, then plated at ~500 cells per well in 6-well plates. After 18 hours recovery, drugs were applied at 0, 0.5x, 1x, 2x, 4x and 8x GI 50 multiples for various times. Drug containing media was removed, cells washed with PBS, then incubated for 5-8 days in drug-free media. Colonies (containing >30 cells) were counted after staining/fixation with 0.25% crystal violet in 10% paraformaldehyde. Results indicate the %age of colonies formed relative to untreated controls. For assays performed on siRNA-or plasmid-transfected cells, cells were detached and replated 48 hours post-transfection and then (after 6 hours recovery) treated for 18 hours with drug. pCDNA-Chk1 was purchased from Origene and used alongside pCDNA3.1 as a control. siRNAs vs. Mcl-1 (Hs_MCL1_6) and XIAP (Hs_BIRC4_5) were from Qiagen, as was the Allstars negative control siRNA, siNon.
Kinase assays. CDK1/cyclin B, CDK2/cyclin A, CDK7/cyclin H and CDK9/cyclin T1 assays were performed as described in ref. 50 ; Chk1, GSK3β and PDK1 were assayed as described in ref. 23 . IC 50 values were estimated from assays where inhibitor was varied over a 512-fold range (as a 10-point doubling dilution series). Results quoted are the average of ≥2 independent experiments. ATP concentrations were at the K M for the particular kinase in question.
pro-apoptotic properties of BMS-387032 do not increase its ability to suppress long-term proliferative potential above that which can be accounted for by its ability to impose a sustained cell cycle arrest. CDK2 may therefore be the critical target of inhibitors that primarily target transcriptional CDKs, even if they only modulate the cell cycle kinase indirectly via effects on CDK7.
What are the consequences of these findings regarding the mode of action of CDK inhibitors for cancer therapy? We have demonstrated that in one cancer cell line, the sustained inhibition of CDK2 may be sufficient to eliminate proliferative potential. It is not currently clear, whether these results would also be typical of untransformed dividing cells. However, even if most untransformed cells in cycle can withstand 24-hours inhibition of CDK2, it only takes the cells of one vital tissue system to be sensitive for the therapeutic window to be closed. We would also note that while suppression of Mcl-1 or XIAP may not account for CDK inhibitor cytotoxicity in U2-OS cells, it is clearly critical in other systems. [14] [15] [16] Perhaps the key to the successful use of CDK inhibitors in the therapy of malignancy will be to identify those inhibitors that downregulate CDK9 at lower doses than they suppress CDK2 or CDK7 activity (the latter will lead to the first). Such inhibitors should then be used in indications where Mcl-1 suppression evokes apoptosis, such as chronic lymphocytic leukemia. 42, 43 Alternatively, less specific CDK inhibitors may prove useful where they can be applied as a short bolus against Mcl-1 or XIAP-dependent malignancies that succumb to short interruptions of synthesis of these antiapoptotic proteins. Such modalities might kill sensitive tumor cells but leave the proliferative potential of transit amplifying populations in vital organs unaffected.
Materials and Methods
Cell lines and culture conditions. U2-OS (LGC-Promochem) were cultured in DMEM supplemented with fetal calf serum (10%) and penicillin/streptomycin (1%). Transfections were performed with Lipofectamine 2000 in Optimem according to the manufacturers instructions (for all the above: Invitrogen, Paisley, UK). For proliferation assays, cells were plated at 1000-3000 cells/well in 96 well plates and drug applied for 72 hours. TCA fixed cells were stained with sulforhodamine B (SRB) and GI 50 concentrations calculated from inflexion points of dose-response curves using Excel-fit software (IDBS Limited). The Biomass estimates in Figure 2B represent mean SRB staining of 8 wells either fixed prior to drug addition (defined as 100%), 24 hours after drug addition, or after 24 or 48 hours recovery from a 24 hour treatment with VER-54505. Where zVAD-fmk was included it was present for the entire experiment.
Compounds. BMS-387032 and VER-54505 were synthesized as described in refs 9 and 44, respectively. Roscovitine; 45 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB); 46 RGB-286147 (CDK/Crk inhibitor); 47 compound 32 (CDK2/9 inhibitor); 48 and SU-9516, 49 were all obtained from Calbiochem.
Immunoblotting and ELISA analysis. For immunoblotting, cell lysates (containing 15 μg protein) were separated by SDS-PAGE and transferred to PVDF membranes, which were then blocked for 1 hour with TBS-T (20 mM Tris-Cl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) plus 5% non-fat dry milk. After incubation with primary antibody (in blocking solution) for 2 to 18 hours, membranes were washed for 3 x 5 minutes with TBS-T, probed with secondary antibody (in blocking solution) for one hour, then washed 3 x 5 Mode of action of the CDK inhibitor VER-54505
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